Segment Information (Segment Data) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Segment Reporting Information [Line Items]
Sales	$ 23,875,000,000	$ 23,890,000,000	$ 26,643,000,000
Less:
Depreciation	(721,000,000)	(675,000,000)	(698,000,000)
Amortization of intangible assets	(1,631,000,000)	(1,491,000,000)	(1,434,000,000)
Impairment charges	(265,000,000)	(77,000,000)	0
Other operating segment expenses	(16,395,000,000)	(16,445,000,000)	(16,975,000,000)
Operating profit	4,863,000,000	5,202,000,000	7,536,000,000
Identifiable assets	77,542,000,000	84,488,000,000	84,350,000,000
Capital expenditures, gross	1,392,000,000	1,383,000,000	1,118,000,000
Discontinued operations
Less:
Identifiable assets	0	0	4,781,000,000
Other
Segment Reporting Information [Line Items]
Sales	0	0	0
Less:
Depreciation	(9,000,000)	(5,000,000)	(9,000,000)
Amortization of intangible assets	0	0	0
Impairment charges	0	0
Other operating segment expenses	(317,000,000)	(317,000,000)	(313,000,000)
Operating profit	(326,000,000)	(322,000,000)	(322,000,000)
Capital expenditures, gross	4,000,000	100,000,000	6,000,000
Other | Continuing operations
Less:
Identifiable assets	5,522,000,000	8,785,000,000	9,739,000,000
Biotechnology | Operating segments
Segment Reporting Information [Line Items]
Sales	6,759,000,000	7,172,000,000	8,758,000,000
Less:
Depreciation	(151,000,000)	(162,000,000)	(190,000,000)
Amortization of intangible assets	(863,000,000)	(864,000,000)	(812,000,000)
Impairment charges	0	(54,000,000)
Other operating segment expenses	(4,060,000,000)	(4,183,000,000)	(4,748,000,000)
Operating profit	1,685,000,000	1,909,000,000	3,008,000,000
Capital expenditures, gross	447,000,000	417,000,000	405,000,000
Biotechnology | Operating segments | Continuing operations
Less:
Identifiable assets	34,605,000,000	37,421,000,000	37,536,000,000
Life Sciences | Operating segments
Segment Reporting Information [Line Items]
Sales	7,329,000,000	7,141,000,000	7,036,000,000
Less:
Depreciation	(167,000,000)	(129,000,000)	(112,000,000)
Amortization of intangible assets	(576,000,000)	(429,000,000)	(419,000,000)
Impairment charges	(222,000,000)	0
Other operating segment expenses	(5,485,000,000)	(5,374,000,000)	(5,091,000,000)
Operating profit	879,000,000	1,209,000,000	1,414,000,000
Capital expenditures, gross	391,000,000	320,000,000	325,000,000
Life Sciences | Operating segments | Continuing operations
Less:
Identifiable assets	23,211,000,000	23,730,000,000	17,572,000,000
Diagnostics | Operating segments
Segment Reporting Information [Line Items]
Sales	9,787,000,000	9,577,000,000	10,849,000,000
Less:
Depreciation	(394,000,000)	(379,000,000)	(387,000,000)
Amortization of intangible assets	(192,000,000)	(198,000,000)	(203,000,000)
Impairment charges	(43,000,000)	(23,000,000)
Other operating segment expenses	(6,533,000,000)	(6,571,000,000)	(6,823,000,000)
Operating profit	2,625,000,000	2,406,000,000	3,436,000,000
Capital expenditures, gross	550,000,000	546,000,000	382,000,000
Diagnostics | Operating segments | Continuing operations
Less:
Identifiable assets	$ 14,204,000,000	$ 14,552,000,000	$ 14,722,000,000